Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Pol Specenier & Jan B Vermorken. (2013) Cetuximab: its unique place in head and neck cancer treatment. Biologics: Targets and Therapy 7, pages 77-90.
Read now
Read now
Didier Dequanter, Mohammad Shahla, Pascal Paulus & Philippe H Lothaire. (2012) The role of EGFR-targeting strategies in the treatment of head and neck cancer. OncoTargets and Therapy 5, pages 127-131.
Read now
Read now
P Sarita Rajender, D Ramasree, K Bhargavi, M Vasavi & V* Uma. (2010) Selective inhibition of proteins regulating CDK/cyclin complexes: strategy against cancer—a review. Journal of Receptors and Signal Transduction 30:4, pages 206-213.
Read now
Read now
Claire McLarnon, Praneta Kulloo, Hisham Mehanna, Charles Kelly & Vinidh Paleri. (2010) Quality-of-life considerations in treatment of unresectable, recurrent head and neck cancer. Expert Review of Anticancer Therapy 10:3, pages 345-352.
Read now
Read now
Articles from other publishers (29)
Joonas Liedes, Henri Hellström, Oona Rainio, Sarita Murtojärvi, Simona Malaspina, Jussi Hirvonen, Riku Klén & Jukka Kemppainen. (2023) Automatic Segmentation of Head and Neck Cancer from PET-MRI Data Using Deep Learning. Journal of Medical and Biological Engineering 43:5, pages 532-540.
Crossref
Crossref
Nobuhiro Yamakawa, Masahiro Umeda, Yumi Yoshii, Kenji Mitsudo, Makoto Noguchi, Jingo Kusukawa, Akira Katakura, Hideki Nakayama, Masashi Sasaki, Tadahide Noguchi, Michihiro Ueda, Hiroki Bukawa, Kazuhiro Yagihara, Akihisa Horie, Akihiro Miyazaki, Daichi Chikazu, Kei Tomihara, Katsuaki Mishima, Mitsunobu Otsuru, Seiji Asoda, Shigeyoshi Fujiwara, Yoshio Ohyama, Hiroshi Kurita, Hitoshi Kawamata, Masayuki Fukuda, Yukari Shintani, Takanori Kobayashi, Takahiro Kanno, Ichiro Oh‐iwa, Kenji Kawano, Yoshio Yamashita, Wataru Kobayashi, Yoichi Ohiro, Katsuhiro Uzawa, Yoshihide Ota & Tadaaki Kirita. (2023) Multicenter retrospective study of nivolumab for recurrent/metastatic oral squamous cell carcinoma. Oral Diseases.
Crossref
Crossref
Sara Kamali Zonouzi, Sepideh Razi & Nima Rezaei. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology
1
28
.
Tsung-Ming Chen, Chih-Ming Huang, Ming-Shou Hsieh, Chun-Shu Lin, Wei-Hwa Lee, Chi-Tai Yeh & Shao-Cheng Liu. (2022) TRPM7 via calcineurin/NFAT pathway mediates metastasis and chemotherapeutic resistance in head and neck squamous cell carcinoma. Aging 14:12, pages 5250-5270.
Crossref
Crossref
Kohei Okuyama, Keiji Suzuki, Tomofumi Naruse, Hiroki Tsuchihashi, Souichi Yanamoto, Atsushi Kaida, Masahiko Miura, Masahiro Umeda & Shunichi Yamashita. (2021) Prolonged cetuximab treatment promotes p27Kip1-mediated G1 arrest and autophagy in head and neck squamous cell carcinoma. Scientific Reports 11:1.
Crossref
Crossref
Pooja Babbar, AH Rudresha, Lokanatha Dasappa, LinuAbraham Jacob, MC Suresh Babu, KN Lokesh, LK Rajeev, Smitha Saldanha & Vinay Kakkar. (2021) Carboplatin in combination with 3-weekly paclitaxel as first-line therapy in patients with recurrent/metastatic head-and-neck cancers: A regional cancer center experience. Oncology Journal of India 5:2, pages 71.
Crossref
Crossref
A.K. Anand, J.P. Agarwal, A. D'Cruz, P.S. Dattatreya, C. Goswami, A. Joshi, P.K. Julka, V. Noronha, K. Prabhash, R. Ranga Rao, Rejnish Kumar, R. Toprani & V. Saxena. (2021) Evolving multidisciplinary treatment of squamous cell carcinoma of the head and neck in India✰. Cancer Treatment and Research Communications 26, pages 100269.
Crossref
Crossref
Jens K. D. Bentzen, Claus Andrup Kristensen, Marie Overgaard, Carsten Rytter, Kenneth Jensen & Hanne Sand Hansen. (2018) A Non Platinum Regimen for the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Region. Results From an Extended Phase II Study With Paclitaxel and Capecitabine. Frontiers in Oncology 8.
Crossref
Crossref
Souichi Yanamoto, Masahiro Umeda, Mitomu Kioi, Tadaaki Kirita, Tetsuro Yamashita, Hiroyoshi Hiratsuka, Satoshi Yokoo, Hideki Tanzawa, Narikazu Uzawa, Takahiko Shibahara, Yoshihide Ota, Hiroshi Kurita, Masaya Okura, Hiroyuki Hamakawa, Jingo Kusukawa & Iwai Tohnai. (2018) Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma. Cancer Chemotherapy and Pharmacology 81:3, pages 549-554.
Crossref
Crossref
Laura Q.M. Chow, Chihiro Morishima, Keith D. Eaton, Christina S. Baik, Bernardo H. Goulart, Leslie N. Anderson, Kristi L. Manjarrez, Gregory N. Dietsch, James Kyle Bryan, Robert M. Hershberg, Mary L. Disis & Renato G. Martins. (2017) Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN. Clinical Cancer Research 23:10, pages 2442-2450.
Crossref
Crossref
M. Ritter, I. U. Teudt, J. E. Meyer, U. Schr?der, G. Kov?cs & B. Wollenberg. (2016) Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol. Radiation Oncology 11:1.
Crossref
Crossref
Shellese A. Cannonier, Cara B. Gonzales, Kim Ely, Scott A. Guelcher & Julie A. Sterling. (2016) Hedgehog and TGFβ signaling converge on Gli2 to control bony invasion and bone destruction in oral squamous cell carcinoma. Oncotarget 7:46, pages 76062-76075.
Crossref
Crossref
Jean-Claude M. Rwigema, Dan Nguyen, Dwight E. Heron, Allen M. Chen, Percy Lee, Pin-Chieh Wang, John A. Vargo, Daniel A. Low, M. Saiful Huq, Stephen Tenn, Michael L. Steinberg, Patrick Kupelian & Ke Sheng. (2015) 4? Noncoplanar Stereotactic Body Radiation Therapy for Head-and-Neck Cancer: Potential to Improve Tumor Control and Late Toxicity. International Journal of Radiation Oncology*Biology*Physics 91:2, pages 401-409.
Crossref
Crossref
? ?. (2015) Clinical Studies on Induction Chemotherapy Followed by Concurrent Lobaplatin Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. World Journal of Cancer Research 05:01, pages 1-7.
Crossref
Crossref
. 2015. Facharzt Hämatologie Onkologie. Facharzt Hämatologie Onkologie
e1
e79
.
Pol Specenier. 2015. Targeted Therapies for Solid Tumors. Targeted Therapies for Solid Tumors
81
87
.
Lluís Nisa, Daniel Matthias Aebersold, Roland Giger, Yitzhak Zimmer & Michaela Medová. (2014) Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer. Pharmacology & Therapeutics 143:3, pages 337-349.
Crossref
Crossref
V. Patil, V. Noronha, V. Krishna, A. Joshi & K. Prabhash. (2013) Oral Metronomic Chemotherapy in Recurrent, Metastatic and Locally Advanced Head and Neck Cancers. Clinical Oncology 25:6, pages 388.
Crossref
Crossref
A. Hoeben, D. Martin, P.M. Clement, J. Cools & J.S. Gutkind. (2012) Role of GRB2‐associated binder 1 in epidermal growth factor receptor‐induced signaling in head and neck squamous cell carcinoma. International Journal of Cancer 132:5, pages 1042-1050.
Crossref
Crossref
Bego?a Jim?nez, Jos? M. Trigo, Bella I. Pajares, Maria I. S?ez, Cristina Quero, Victor Navarro, Casilda Ll?cer, Laura Medina, Antonio Rueda & Emilio Alba. (2013) Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients. Oral Oncology 49:2, pages 182-185.
Crossref
Crossref
. 2012. Facharzt Hämatologie Onkologie. Facharzt Hämatologie Onkologie
e1
e61
.
Pol Specenier, Marika Rasschaert, Philippe Vroman, Jan Van den Brande, Joke Dyck, Dirk Schrijvers, Manon T. Huizing & Jan B. Vermorken. (2011) Weekly Docetaxel in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. American Journal of Clinical Oncology 34:5, pages 472-477.
Crossref
Crossref
Jean-Claude M. Rwigema, Dwight E. Heron, Robert L. Ferris, Regiane S. Andrade, Michael K. Gibson, Yong Yang, Cihat Ozhasoglu, Athanassios E. Argiris, Jennifer R. Grandis & Steven A. Burton. (2011) The Impact of Tumor Volume and Radiotherapy Dose on Outcome in Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and Neck Treated With Stereotactic Body Radiation Therapy. American Journal of Clinical Oncology 34:4, pages 372-379.
Crossref
Crossref
Chen Guang Yang, Joseph Ciccolini, Aurore Blesius, Laetitia Dahan, Danielle Bagarry-Liegey, Caroline Brunet, Arthur Varoquaux, Nicolas Frances, Hafedh Marouani, Antoine Giovanni, Rose-Marie Ferri-Dessens, Mohamed Chefrour, Roger Favre, Florence Duffaud, Jean-François Seitz, Michel Zanaret, Bruno Lacarelle & Cédric Mercier. (2010) DPD-based adaptive dosing of 5-FU in patients with head and neck cancer: impact on treatment efficacy and toxicity. Cancer Chemotherapy and Pharmacology 67:1, pages 49-56.
Crossref
Crossref
Lisa Licitra & Patrizia OlmiLaura D. Locati & Marco Merlano. 2011. Tumori della testa e del collo. Tumori della testa e del collo
195
207
.
Xu Zhou, Wantao Chen, Yuexing Zhang, Jian Sun, Qing Wang & Youcheng Yu. (2009) Potential therapeutic strategy for oral squamous cell carcinoma by ErbB3-binding protein 1 gene transfer. Journal of Cancer Research and Clinical Oncology 136:6, pages 891-896.
Crossref
Crossref
Pol Specenier & Jan B Vermorken. (2010) Advances in the systemic treatment of head and neck cancers. Current Opinion in Oncology 22:3, pages 200-205.
Crossref
Crossref
George Fountzilas, Anna Fragkoulidi, Anna Kalogera-Fountzila, Martha Nikolaidou, Mattheos Bobos, Julien Calderaro, Felipe Andreiuolo & Marios Marselos. (2009) A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemotherapy and Pharmacology 65:4, pages 649-660.
Crossref
Crossref
Gabriela Studer, Klaus W Graetz & Christoph Glanzmann. (2008) Outcome in recurrent head neck cancer treated with salvage-IMRT. Radiation Oncology 3:1.
Crossref
Crossref